Table 1. Participant Characteristics and Standardized Mortality Ratios.
| Characteristic | All SJLIFE eligible survivors (n = 9440)a | Adult on-campus SJLIFE participants (n = 3407)b | ||||
|---|---|---|---|---|---|---|
| No. (%) | SMR (95% CI) | No. (%) | SMR (95% CI) | |||
| Alive | Dead | Alive | Dead | |||
| Overall | 8159 | 1281 | 7.6 (7.2-8.1) | 3284 | 123 | 3.8 (3.1-4.5) |
| Race and ethnicity | ||||||
| Hispanic | 333 (4.1) | 30 (2.3) | 13.6 (9.2-19.4) | 72 (2.2) | 1 (0.8) | 2.7 (0-15.2) |
| Non-Hispanic Black | 1387 (17.0) | 201 (15.7) | 8.5 (7.4-9.8) | 483 (14.7) | 15 (12.2) | 3.7 (2.1-6.1) |
| Non-Hispanic White | 6151 (75.4) | 955 (74.6) | 6.9 (6.5-7.4) | 2677 (81.5) | 106 (86.2) | 3.8 (3.1-4.6) |
| Otherc | 288 (3.5) | 95 (7.4) | 21.8 (17.6-26.6) | 52 (1.6) | 1 (0.8) | 2.4 (0-13.4) |
| Sex | ||||||
| Male | 4437 (54.4) | 770 (60.1) | 6.3 (5.9-6.8) | 1712 (52.1) | 75 (61.0) | 3.5 (2.8-4.4) |
| Female | 3722 (45.6) | 511 (39.9) | 11.0 (10.1-12.0) | 1572 (47.9) | 48 (39.0) | 4.3 (3.1-5.6) |
| Age at diagnosis, y | ||||||
| 0-4 | 3532 (43.3) | 453 (35.4) | 8.9 (8.1-9.7) | 1217 (37.1) | 33 (26.8) | 3.4 (2.3-4.7) |
| 5-9 | 1850 (22.7) | 291 (22.7) | 8.0 (7.1-9.0) | 770 (23.4) | 26 (21.1) | 3.6 (2.3-5.2) |
| 10-14 | 1587 (19.5) | 292 (22.8) | 7.0 (6.2-7.8) | 761 (23.2) | 31 (25.2) | 3.9 (2.6-5.5) |
| 15-19 | 1123 (13.8) | 220 (17.2) | 6.2 (5.4-7.1) | 514 (15.7) | 30 (24.4) | 4.2 (2.8-6.0) |
| ≥20 | 67 (0.8) | 25 (2.0) | 7.0 (4.5-10.3) | 22 (0.7) | 3 (2.4) | 5.9 (1.2-17.1) |
| Decade of diagnosis | ||||||
| 1960-1969 | 139 (1.7) | 126 (9.8) | 6.6 (5.5-7.9) | 85 (2.6) | 13 (10.6) | 3.9 (2.1-6.7) |
| 1970-1979 | 804 (9.9) | 352 (27.5) | 6.4 (5.7-7.1) | 525 (16.0) | 48 (39.0) | 4.6 (3.4-6.1) |
| 1980-1989 | 1645 (20.2) | 351 (27.4) | 6.5 (5.8-7.2) | 1042 (31.7) | 40 (32.5) | 3.6 (2.6-4.9) |
| 1990-1999 | 2089 (25.6) | 254 (19.8) | 8.6 (7.6-9.7) | 1210 (36.8) | 18 (14.6) | 2.6 (1.5-4.1) |
| 2000-2012 | 3482 (42.7) | 198 (15.5) | 19.3 (16.7-22.2) | 422 (12.9) | 4 (3.3) | 4.4 (1.2-11.3) |
| Age at assessment, y | ||||||
| 5-9 | 377 (4.6) | 107 (8.4) | 1047.4 (858.4-1265.7) | NA | NA | NA |
| 10-14 | 778 (9.5) | 218 (17.0) | 377.7 (329.2-431.3) | NA | NA | NA |
| 15-19 | 1055 (12.9) | 208 (16.2) | 87.7 (76.1-100.4) | 22 (0.7) | 0 | 0 (0-982.3) |
| 20-24 | 1134 (13.9) | 179 (14.0) | 29.6 (25.4-34.2) | 347 (10.6) | 3 (2.4) | 5.1 (1.0-14.8) |
| 25-29 | 1110 (13.6) | 141 (11.0) | 11.5 (9.7-13.6) | 566 (17.2) | 9 (7.3) | 3.6 (1.6-6.8) |
| 30-39 | 2026 (24.8) | 197 (15.4) | 4.5 (3.9-5.2) | 1284 (39.1) | 34 (27.6) | 3.8 (2.6-5.3) |
| 40-49 | 1210 (14.8) | 152 (11.9) | 2.9 (2.4-3.3) | 767 (23.4) | 41 (33.3) | 3.9 (2.8-5.3) |
| ≥50 | 469 (5.7) | 79 (6.2) | 1.6 (1.3-2.0) | 298 (9.1) | 36 (29.3) | 3.5 (2.5-4.9) |
| Survival after diagnosis, No. of y | ||||||
| 5-9 | 1572 (19.3) | 539 (42.1) | 24.8 (22.8-27.0) | 27 (0.8) | 0 | 0 (0-225.1) |
| 10-14 | 1386 (17.0) | 186 (14.5) | 7.3 (6.3-8.5) | 209 (6.4) | 4 (3.3) | 3.3 (0.9-8.6) |
| 15-19 | 1205 (14.8) | 137 (10.7) | 5.1 (4.3-6.1) | 508 (15.5) | 5 (4.1) | 2.1 (0.9-4.4) |
| 20-24 | 1064 (13.0) | 109 (8.5) | 4.3 (3.6-5.2) | 670 (20.4) | 19 (15.4) | 4.0 (2.3-6.3) |
| 25-29 | 857 (10.5) | 84 (6.6) | 3.9 (3.1-4.8) | 542 (16.5) | 18 (14.6) | 3.2 (1.9-5.1) |
| 30-34 | 836 (10.2) | 83 (6.5) | 4.2 (3.3-5.2) | 537 (16.4) | 18 (14.6) | 3.0 (1.8-4.7) |
| 35-39 | 650 (8.0) | 82 (6.4) | 5.8 (4.6-7.2) | 413 (12.6) | 31 (25.2) | 5.8 (3.9-8.1) |
| ≥40 | 589 (7.2) | 61 (4.8) | 4.5 (3.4-5.7) | 378 (11.5) | 28 (22.8) | 4.0 (2.6-5.9) |
| Cancer diagnosis | ||||||
| Leukemia | ||||||
| Acute lymphoblastic | 2212 (27.1) | 303 (23.7) | 6.2 (5.5-6.9) | 1054 (32.1) | 25 (20.3) | 2.2 (1.4-3.2) |
| Acute myeloid | 379 (4.6) | 38 (3.0) | 7.9 (5.6-10.8) | 125 (3.8) | 4 (3.3) | 4.5 (1.2-11.6) |
| Chronic myeloid | 13 (0.2) | 2 (0.2) | 13.8 (1.5-49.8) | 3 (0.1) | 0 | 15.9 (1.8-57.3) |
| Other | 61 (0.7) | 14 (1.1) | 13.3 (7.3-22.3) | 22 (0.7) | 2 (1.6) | 0 (0-242.9) |
| Central nervous system tumor | ||||||
| Astrocytoma | 618 (7.6) | 86 (6.7) | 15.5 (12.4-19.2) | 181 (5.5) | 4 (3.3) | 4.3 (1.2-11.1) |
| Medulloblastoma | 341 (4.2) | 54 (4.2) | 17.8 (13.3-23.2) | 92 (2.8) | 3 (2.4) | 5.1 (1.0-15.0) |
| Ependymoma | 188 (2.3) | 64 (5.0) | 60.3 (46.4-77.0) | 37 (1.1) | 4 (3.3) | 18.9 (5.1-48.5) |
| Other | 165 (2.0) | 20 (1.6) | 14.6 (8.9-22.6) | 32 (1.0) | 0 | 0 (0-21.1) |
| Craniopharyngioma | 141 (1.7) | 13 (1.0) | 18.4 (9.8-31.5) | 31 (0.9) | 0 | 0 (0-26.3) |
| Hodgkin lymphoma | 682 (8.4) | 185 (14.4) | 7.2 (6.2-8.4) | 363 (11.1) | 45 (36.6) | 8.4 (6.1-11.3) |
| Non-Hodgkin lymphoma | 503 (6.2) | 74 (5.8) | 4.6 (3.6-5.8) | 236 (7.2) | 8 (6.5) | 3.2 (1.4-6.2) |
| Kidney | 473 (5.8) | 50 (3.9) | 5.4 (4.0-7.2) | 214 (6.5) | 6 (4.9) | 3.5 (1.3-7.6) |
| Neuroblastoma | 379 (4.6) | 73 (5.7) | 12.0 (9.4-15.1) | 149 (4.5) | 1 (0.8) | 0.9 (0-5.0) |
| Soft tissue sarcoma | 492 (6.0) | 77 (6.0) | 6.9 (5.5-8.6) | 210 (6.4) | 5 (4.1) | 2.8 (0.9-6.6) |
| Ewing sarcoma | 198 (2.4) | 66 (5.2) | 10.1 (7.8-12.8) | 100 (3.0) | 2 (1.6) | 1.5 (0.2-5.4) |
| Osteosarcoma | 237 (2.9) | 52 (4.1) | 5.9 (4.4-7.7) | 126 (3.8) | 4 (3.3) | 2.0 (0.5-5.1) |
| Retinoblastoma | 428 (5.2) | 30 (2.3) | 6.6 (4.4-9.4) | 96 (2.9) | 3 (2.4) | 3.4 (0.7-10.0) |
| Germ cell tumor | 179 (2.2) | 18 (1.4) | 5.0 (3.0-7.9) | 81 (2.5) | 2 (1.6) | 3.6 (0.4-13.1) |
| Liver cancers | 65 (0.8) | 5 (0.4) | 4.7 (1.5-11.0) | 22 (0.7) | 1 (0.8) | 7.8 (0.1-43.4) |
| Melanoma | 71 (0.9) | 7 (0.5) | 5.8 (2.3-12.0) | 21 (0.6) | 0 | 0 (0-17.6) |
| Nasopharyngeal carcinoma | 46 (0.6) | 15 (1.2) | 9.4 (5.2-15.4) | 22 (0.7) | 4 (3.3) | 11.7 (3.2-30.0) |
| Histiocytosis | 138 (1.7) | 7 (0.5) | 2.0 (0.8-4.1) | 21 (0.6) | 0 | 0 (0-22.2) |
| Other cancers | 150 (1.8) | 28 (2.2) | 12.1 (8.0-17.5) | 46 (1.4) | 0 | 0 (0-10.0) |
| Cancer treatment | ||||||
| Radiotherapy | ||||||
| Total body | ||||||
| No | 7898 (96.8) | 1222 (95.4) | 7.4 (7.0-7.8) | 3188 (97.1) | 121 (98.4) | 3.8 (3.1-4.5) |
| Yes | 261 (3.2) | 39 (3.0) | 13.1 (9.3-17.9) | 96 (2.9) | 2 (1.6) | 3.9 (0.4-14.1) |
| Cranial | ||||||
| No | 5849 (71.7) | 689 (53.8) | 6.2 (5.7-6.7) | 2267 (69.0) | 78 (63.4) | 3.8 (3.0-4.7) |
| Yes | 2310 (28.3) | 577 (45.0) | 10.2 (9.4-11.1) | 1017 (31.0) | 45 (36.6) | 3.8 (2.7-5.0) |
| Craniospinal | ||||||
| No | 7793 (95.5) | 1091 (85.2) | 6.7 (6.3-7.1) | 3175 (96.7) | 116 (94.3) | 3.7 (3.0-4.4) |
| Yes | 365 (4.5) | 88 (6.9) | 16.3 (13.1-20.1) | 109 (3.3) | 7 (5.7) | 6.5 (2.6-13.3) |
| Chest | ||||||
| No | 6418 (78.7) | 712 (55.6) | 5.9 (5.4-6.3) | 2528 (77.0) | 56 (45.5) | 2.4 (1.8-3.1) |
| Yes | 1741 (21.3) | 551 (43.0) | 11.9 (10.9-12.9) | 756 (23.0) | 67 (54.5) | 7.5 (5.8-9.5) |
| Abdominal or pelvic | ||||||
| No | 6420 (78.7) | 716 (55.9) | 6.0 (5.6-6.5) | 2528 (77.0) | 58 (47.2) | 2.4 (1.9-3.2) |
| Yes | 1739 (21.3) | 547 (42.7) | 11.2 (10.3-12.2) | 756 (23.0) | 65 (52.8) | 7.2 (5.6-9.2) |
| Other site(s) | ||||||
| No | 7802 (95.6) | 1136 (88.7) | 7.2 (6.8-7.6) | 3127 (95.2) | 119 (96.7) | 3.8 (3.2-4.6) |
| Yes | 356 (4.4) | 38 (3.0) | 4.0 (2.8-5.4) | 157 (4.8) | 4 (3.3) | 2.3 (0.6-5.9) |
| Chemotherapy | ||||||
| Alkylators | ||||||
| No | 3620 (44.4) | 413 (32.2) | 6.6 (6.0-7.3) | 1368 (41.7) | 38 (30.9) | 3.3 (2.3-4.6) |
| Yes | 4539 (55.6) | 847 (66.1) | 8.0 (7.5-8.6) | 1916 (58.3) | 85 (69.1) | 4.0 (3.2-4.9) |
| Anthracyclines | ||||||
| No | 3827 (46.9) | 704 (55.0) | 7.9 (7.3-8.5) | 1365 (41.6) | 75 (61.0) | 4.8 (3.7-6.0) |
| Yes | 4332 (53.1) | 557 (43.5) | 7.1 (6.5-7.7) | 1919 (58.4) | 48 (39.0) | 2.8 (2.1-3.8) |
| Platinum | ||||||
| No | 6694 (82.0) | 1001 (78.1) | 6.5 (6.1-6.9) | 2868 (87.3) | 108 (87.8) | 3.6 (2.9-4.3) |
| Yes | 1465 (18.0) | 260 (20.3) | 19.9 (17.6-22.5) | 416 (12.7) | 15 (12.2) | 5.9 (3.3-9.7) |
| Anthracycline dose, mg/m2 | ||||||
| None | 3827 (46.9) | 704 (55.0) | 7.9 (7.3-8.5) | 1365 (41.6) | 75 (61.0) | 4.8 (3.7-6.0) |
| 0.1 to <250.0 | 3383 (41.5) | 320 (25.0) | 5.9 (5.2-6.5) | 1481 (45.1) | 35 (28.5) | 3.0 (2.1-4.1) |
| ≥250.0 | 892 (10.9) | 203 (15.8) | 8.8 (7.7-10.1) | 433 (13.2) | 13 (10.6) | 2.6 (1.4-4.4) |
| ADI, % | ||||||
| 1-10d,e | NA | NA | NA | 326 (9.9) | 2 (1.6) | 0.6 (0.1-2.2) |
| 11-50 | NA | NA | NA | 1278 (38.9) | 30 (24.4) | 2.4 (1.6-3.4) |
| 51-80 | NA | NA | NA | 942 (28.7) | 40 (32.5) | 4.1 (2.9-5.6) |
| 81-100 | NA | NA | NA | 590 (18.0) | 32 (26.0) | 5.7 (3.9-8.0) |
| Unassigned | NA | NA | NA | 148 (4.5) | 19 (15.4) | 12.7 (7.6-19.8) |
| Annual household income, $e,f | ||||||
| <20 000 | NA | NA | NA | 483 (14.7) | 19 (15.4) | 4.3 (2.6-6.8) |
| 20 000-59 000 | NA | NA | NA | 1023 (31.2) | 47 (38.2) | 4.5 (3.3-6.0) |
| 60 000-99 000 | NA | NA | NA | 662 (20.2) | 22 (17.9) | 3.1 (1.9-4.6) |
| ≥100 000 | NA | NA | NA | 566 (17.2) | 15 (12.2) | 2.1 (1.2-3.5) |
| Missing | NA | NA | NA | 550 (16.7) | 20 (16.3) | 5.4 (3.3-8.3) |
| Health insurance statuse | ||||||
| None | NA | NA | NA | 698 (21.3) | 25 (20.3) | 3.7 (2.4-5.4) |
| Public | NA | NA | NA | 542 (16.5) | 47 (38.2) | 9.2 (6.8-12.3) |
| Private | NA | NA | NA | 1949 (59.3) | 46 (37.4) | 2.3 (1.7-3.0) |
| Missing | NA | NA | NA | 95 (2.9) | 5 (4.1) | 7.4 (2.4-17.2) |
Abbreviations: ADI, area deprivation index; NA, not applicable; SJLIFE, St Jude Lifetime Cohort; SMR, standardized mortality ratio.
a
Follow-up began 5 years after cancer diagnosis.
b
Follow-up began after the baseline on-campus assessment. Limited to adult (aged ≥18 years) SJLIFE participants with an on-campus visit before December 31, 2016.
c
Other race and ethnicity category includes 33 Black and 139 White participants with unknown Hispanic ethnicity status, 13 participants with unknown race and unknown Hispanic ethnicity status, 8 participants of other races with unknown Hispanic ethnicity status, and 190 participants of other races with non-Hispanic ethnicity (8 American Indian or Alaska Native, 41 Asian, 14 Asian and White, 26 Black and White, 11 multiple races [not specified], 5 Pacific Islander, 78 other races [not specified], and 7 missing).
d
Reference category.
e
Data were not available for nonparticipants.
f
Income was adjusted to 2016 dollars using inflation rate of 3% per year.